Acceleron Pharma Inc (NASDAQ:XLRN) Shares Sold by Tiverton Asset Management LLC

Tiverton Asset Management LLC trimmed its position in Acceleron Pharma Inc (NASDAQ:XLRN) by 87.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,603 shares of the biopharmaceutical company’s stock after selling 33,097 shares during the period. Tiverton Asset Management LLC’s holdings in Acceleron Pharma were worth $189,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. FMR LLC boosted its stake in Acceleron Pharma by 6.3% in the first quarter. FMR LLC now owns 7,363,953 shares of the biopharmaceutical company’s stock valued at $342,939,000 after acquiring an additional 435,414 shares in the last quarter. Westfield Capital Management Co. LP boosted its stake in Acceleron Pharma by 6.5% in the first quarter. Westfield Capital Management Co. LP now owns 1,377,123 shares of the biopharmaceutical company’s stock valued at $64,133,000 after acquiring an additional 84,410 shares in the last quarter. TimesSquare Capital Management LLC boosted its stake in Acceleron Pharma by 29.5% in the first quarter. TimesSquare Capital Management LLC now owns 920,715 shares of the biopharmaceutical company’s stock valued at $42,878,000 after acquiring an additional 209,900 shares in the last quarter. Eagle Asset Management Inc. boosted its stake in Acceleron Pharma by 3.4% in the second quarter. Eagle Asset Management Inc. now owns 908,330 shares of the biopharmaceutical company’s stock valued at $37,314,000 after acquiring an additional 29,753 shares in the last quarter. Finally, Artisan Partners Limited Partnership boosted its stake in Acceleron Pharma by 22.5% in the first quarter. Artisan Partners Limited Partnership now owns 591,918 shares of the biopharmaceutical company’s stock valued at $27,566,000 after acquiring an additional 108,751 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

Shares of NASDAQ XLRN traded down $0.15 during midday trading on Thursday, reaching $46.47. The company had a trading volume of 11,225 shares, compared to its average volume of 368,642. The business’s 50-day simple moving average is $44.35 and its 200 day simple moving average is $42.89. The stock has a market cap of $2.41 billion, a P/E ratio of -17.89 and a beta of 1.23. Acceleron Pharma Inc has a 1 year low of $37.01 and a 1 year high of $59.59. The company has a current ratio of 17.11, a quick ratio of 17.11 and a debt-to-equity ratio of 0.05.



Acceleron Pharma (NASDAQ:XLRN) last issued its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.10). Acceleron Pharma had a negative return on equity of 29.51% and a negative net margin of 318.84%. The business had revenue of $27.67 million for the quarter, compared to analysts’ expectations of $28.72 million. During the same period last year, the business earned ($0.63) EPS. The company’s revenue for the quarter was up 649.9% on a year-over-year basis. Analysts predict that Acceleron Pharma Inc will post -2.33 earnings per share for the current year.

In related news, VP Adam M. Veness sold 3,268 shares of the firm’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $45.00, for a total transaction of $147,060.00. Following the completion of the transaction, the vice president now owns 16,925 shares of the company’s stock, valued at $761,625. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Joseph S. Zakrzewski bought 5,000 shares of Acceleron Pharma stock in a transaction that occurred on Friday, June 14th. The shares were acquired at an average cost of $38.05 per share, with a total value of $190,250.00. Following the acquisition, the director now owns 12,750 shares of the company’s stock, valued at $485,137.50. The disclosure for this purchase can be found here. In the last three months, insiders have sold 88,416 shares of company stock valued at $3,636,515. 2.50% of the stock is currently owned by corporate insiders.

Several brokerages have weighed in on XLRN. HC Wainwright restated a “buy” rating and issued a $69.00 target price on shares of Acceleron Pharma in a research note on Friday, September 6th. Citigroup reaffirmed a “buy” rating and issued a $66.00 price target on shares of Acceleron Pharma in a report on Friday, May 24th. ValuEngine raised shares of Acceleron Pharma from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 8th. Credit Suisse Group set a $58.00 price target on shares of Acceleron Pharma and gave the stock a “buy” rating in a report on Monday, August 26th. Finally, Morgan Stanley set a $53.00 price target on shares of Acceleron Pharma and gave the stock a “hold” rating in a report on Monday, July 15th. Six investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $60.10.

Acceleron Pharma Company Profile

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

Further Reading: What are the Benefits of Index Funds?

Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc (NASDAQ:XLRN).

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.